Partnerships

Open-Innovation Strategy

HiFiBiO Therapeutics is committed to working with leading pharmaceutical and biotechnology companies, as well as academic and research institutions to rapidly advance high-quality innovative therapies that can address the unmet medical needs of patients around the world.

Our team is fully committed to open innovation. Our lead assets are open for partnerships in clinical studies.

We are also applying our differentiated single-cell profiling capabilities to address pain points in the clinical development of novel therapeutics. Our industry leading proprietary CelliGOTM platform and unique DISTM capabilities offer novel pathways for accelerating the discovery and development of high-quality therapeutic antibodies. They also enable biomarker discovery for advanced patient stratification and enhanced probability of clinical success.

We are currently working with several pharma partners to discover and validate novel therapeutic targets, and to identify rare functional antibodies against particularly complex targets.

Contact us today to learn more about our open-innovation strategies and partnerships

  • By submitting this form you agree to our Privacy Policy.

We welcome inquiries from prospective partners interested in

Pipeline

  • Partnering our advanced immunomodulatory programs for joint IND filings and/or clinical trials
  • Identifying innovative ideas for novel targeting and immunomodulation mechanisms
  • Exploring innovative technologies and platforms that help generate the best therapeutic molecules

Single-cell platform technologies

  • Discovering and validating novel targets for antibodies or other therapeutic approaches
  • Generating high quality therapeutic antibodies against targets of interest, including functional antibodies against complex targets (e.g. GPCRs, ion channels)
  • Discovering and validating biomarkers for patient stratification through our DISTM platform
  • Further advancing our single-cell platform through other enabling applications and technologies
  • Discovering therapeutics and tool antibodies from patient samples
  • Profiling tumor microenvironment

Other Areas

  • Developing emerging technologies for antibody therapeutics
  • Boosting big data analysis/processing capabilities through specialized AI/machine learning platforms

Pipeline

  • Partnering our advanced immunomodulatory programs for joint IND filings and/or clinical trials
  • Identifying innovative ideas for novel targeting and immunomodulation mechanisms
  • Exploring innovative technologies and platforms that help generate the best therapeutic molecules

Single-cell platform technologies

  • Discovering and validating novel targets for antibodies or other therapeutic approaches
  • Generating high quality therapeutic antibodies against targets of interest, including functional antibodies against complex targets (e.g. GPCRs, ion channels)
  • Discovering and validating biomarkers for patient stratification through our DISTM platform
  • Further advancing our single-cell platform through other enabling applications and technologies
  • Discovering therapeutics and tool antibodies from patient samples
  • Profiling tumor microenvironment

Other Areas

  • Developing emerging technologies for antibody therapeutics
  • Boosting big data analysis/processing capabilities through specialized AI/machine learning platforms

Partnership Highlights

Research Collaboration to Develop Technology for the Treatment of Cancer

Read More

Research Collaboration to Develop Technology for the Treatment of Cancer

Read More

Read our article in Drug Discovery Today for more information on our open-innovation strategy

Read More
Ready for the next steps? Contact us to learn more